Sotera Health (Nasdaq: SHC) lifts 2026 outlook on strong Q2 growth
Rhea-AI Filing Summary
Sotera Health Company reported Q2 2026 net revenues of $321.4 million, up 9.2% year over year, with net income of $53.6 million or $0.19 per diluted share versus $8.0 million or $0.03 in Q2 2025. Adjusted EBITDA rose 10.0% to $165.7 million, delivering a 51.6% margin, and Adjusted EPS increased 30% to $0.26.
All three segments grew on a constant-currency basis, led by Nordion. For the first half of 2026, net revenues reached $601.4 million and net income $80.2 million. Sotera ended June 30, 2026 with $2.23 billion of total debt, $356.7 million of cash, a Net Leverage Ratio of 3.0x within its 2.0x–3.0x target range, and about $950 million of liquidity. A repriced term loan is expected to save approximately $3.5 million of annual interest. The company raised its 2026 outlook, guiding net revenues to $1.236–$1.254 billion, Adjusted EBITDA to $634–$643 million, Adjusted EPS to $0.95–$1.01, and capital expenditures to $200–$225 million.
Positive
- Profitability strengthened sharply: Q2 2026 net income rose to $53.6 million (EPS $0.19) from $8.0 million (EPS $0.03) in Q2 2025, while Adjusted EPS increased 30% to $0.26.
- Top-line and margin expansion: Q2 net revenues grew 9.2% to $321.4 million; Adjusted EBITDA increased 10.0% to $165.7 million, with Adjusted EBITDA margin improving to 51.6%.
- Guidance raised with deleveraging: 2026 net revenue outlook lifted to $1.236–$1.254 billion and Adjusted EBITDA to $634–$643 million, alongside a Net Leverage Ratio of 3.0x and expected $3.5 million annual interest savings from term loan repricing.
Negative
- None.
Filing Explained
The company reports that its final private equity sponsor secondary offering is complete and that no sponsor ownership remains. This changes the ownership composition by removing the sponsor group as a disclosed holder; the filing describes a secondary offering rather than an issuer share issuance.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 Net Revenues: $321.4 million
Q2 2026 Net Income: $53.6 million
Q2 2026 Adjusted EBITDA: $165.7 million
+5 more
8 metrics
Q2 2026 Net Revenues
$321.4 million
Quarter ended June 30, 2026; up 9.2% year over year
Q2 2026 Net Income
$53.6 million
Quarter ended June 30, 2026; compared with $8.0 million in Q2 2025
Q2 2026 Adjusted EBITDA
$165.7 million
Quarter ended June 30, 2026; 10.0% growth, 51.6% margin
Net Leverage Ratio
3.0x
As of June 30, 2026; within long-term 2.0x–3.0x target range
Total Debt
$2.23 billion
As of June 30, 2026; consolidated debt including finance leases
Cash and Cash Equivalents
$356.7 million
As of June 30, 2026; unrestricted cash balance
2026 Net Revenue Outlook
$1.236–$1.254 billion
Full-year 2026 guidance range on a constant-currency basis
2026 Adjusted EBITDA Outlook
$634–$643 million
Full-year 2026 guidance range on a constant-currency basis
Key Terms
Adjusted EBITDA, Adjusted EPS, Net Leverage Ratio, constant currency, +2 more
6 terms
Adjusted EBITDA financial
"Q2 2026 Adjusted EBITDA increased 10.0%, or 8.7% on a constant currency basis"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Adjusted EPS financial
"Q2 2026 Adjusted EPS of $0.26, an increase of 30% per diluted share"
Adjusted earnings per share (adjusted eps) is a measure of a company's profit per share that has been modified to exclude certain one-time or unusual items, such as costs from restructuring or asset sales. It provides a clearer picture of the company’s core performance by removing events that may distort the usual earnings. Investors use adjusted eps to better understand a company's ongoing profitability and compare it more accurately over time.
Net Leverage Ratio financial
"June 30, 2026, Net Leverage Ratio of 3.0x; achieved long-term target range"
The net leverage ratio measures how much debt a company has compared to its available assets or earnings, after accounting for its cash and liquid assets. It helps investors understand how heavily a company relies on borrowed money to finance its operations and growth. A higher ratio indicates greater financial risk, while a lower ratio suggests a more cautious approach to borrowing.
constant currency financial
"net revenues increased 9.1% to $398 million, or 6.6% on a constant currency basis"
Constant currency is a way of measuring financial results that removes the effects of changes in currency exchange rates. It allows for a clearer comparison of a company's performance over time by showing what the numbers would look like if exchange rates had stayed the same. This helps investors understand whether growth comes from actual business improvements or just currency fluctuations.
asset retirement obligation financial
"Represents non-cash accretion of asset retirement obligations related to Co-60 gamma and EO facilities"
A liability recorded for the future cost to retire, dismantle or clean up a long-lived asset — for example removing an oil rig, closing a mine, or decommissioning a plant. Investors care because it reduces reported profit and ties up capital: companies must estimate and set aside money now for a known future expense, and changes to that estimate can swing earnings, debt ratios and the company’s cash needs much like setting aside savings to repair or return a rented property later.
ethylene oxide technical
"supply chain continuity, particularly for the supply of ethylene oxide and Cobalt-60"
Ethylene oxide is a flammable, colorless gas used industrially to make plastics and other chemicals and as a sterilizing agent for medical equipment. Investors should care because its use and emissions are tightly regulated—like a tool that can both build products and create legal or cleanup costs—so changes in safety findings, permits, or supply disruptions can affect manufacturing, liabilities, and company valuations.
Earnings Snapshot
Net revenues: $321.4 million · Guidance included
quarter ended June 30, 2026
Net revenues
$321.4 million
+9.2% vs Q2 2025
Net income
$53.6 million
vs $8.0 million in Q2 2025
Diluted EPS
$0.19
vs $0.03 in Q2 2025
Adjusted EBITDA
$165.7 million
+10.0% vs Q2 2025
Adjusted EPS
$0.26
+30% per diluted share vs Q2 2025
Guidance
For 2026, Sotera Health raised guidance to net revenues of $1.236–$1.254 billion, Adjusted EBITDA of $634–$643 million, Adjusted EPS of $0.95–$1.01, interest expense of $135–$142 million, a 27.0%–28.0% tax rate applicable to Adjusted Net Income, and capital expenditures of $200–$225 million.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Sotera Health (SHC) perform financially in Q2 2026?
Sotera Health delivered Q2 2026 net revenues of $321.4 million, up 9.2% year over year, and net income of $53.6 million, or $0.19 per diluted share, versus $8.0 million and $0.03 in Q2 2025.
What were Sotera Health (SHC)’s key non-GAAP metrics in Q2 2026?
The company reported Adjusted EBITDA of $165.7 million, up 10.0%, with a 51.6% Adjusted EBITDA margin. Adjusted EPS was $0.26, a 30% increase per diluted share compared with the prior-year quarter.
How strong is Sotera Health (SHC)’s balance sheet and leverage?
As of June 30, 2026, Sotera Health had $2.23 billion of total debt and $356.7 million of cash, resulting in a Net Leverage Ratio of 3.0x and available liquidity of about $950 million, within its long-term target range.
What 2026 outlook did Sotera Health (SHC) provide?
For full-year 2026, Sotera Health raised guidance to net revenues of $1.236–$1.254 billion and Adjusted EBITDA of $634–$643 million, with Adjusted EPS expected between $0.95 and $1.01 and capital expenditures of $200–$225 million.
How did Sotera Health (SHC)’s business segments perform in Q2 2026?
In Q2 2026, Sterigenics revenues were $211.6 million (up 8.6%), Nordion $49.1 million (up 15.8%), and Nelson Labs $60.7 million (up 6.3%), all on a reported basis, with each segment showing constant-currency revenue growth and margin improvements or resilience.
What capital and financing actions did Sotera Health (SHC) highlight?
Sotera Health reported net cash from operating activities of $117.9 million for the first half of 2026, capital expenditures of $92.6 million, a repriced term loan expected to save about $3.5 million annually in interest, and completion of a final private equity sponsor secondary offering.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________
FORM 8-K
_______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 6, 2026
_______________________
(Exact Name of Registrant as Specified in its Charter)
_______________________
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of Principal Executive Offices) (Zip Code)
(440 ) 262-1410
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_______________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 6, 2026, Sotera Health Company (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2026. The Company will hold its previously announced conference call on August 6, 2026, at 9:00 a.m. Eastern Time to discuss its financial results for the quarter. A copy of the Press Release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly incorporated by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |||||||
| 99.1 | Press Release, dated August 6, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Sotera Health Company (Registrant) | |||||||||||
| Date: August 6, 2026 | By: | /s/ Jonathan M. Lyons | |||||||||
| Jonathan M. Lyons | |||||||||||
| Senior Vice President and Chief Financial Officer | |||||||||||
Exhibit 99.1
Sotera Health Delivers Strong Second-Quarter and
First-Half 2026 Results and Raises FY 2026 Outlook
•Q2 2026 net revenues increased 9.2% or 8.0% on a constant currency basis(1) compared to Q2 2025
•Q2 2026 net income of $54 million or $0.19 per diluted share, compared to net income of $8 million or $0.03 per diluted share in Q2 2025
•Q2 2026 Adjusted EBITDA(1) increased 10.0%, or 8.7% on a constant currency basis
•Q2 2026 Adjusted EPS(1) of $0.26, an increase of 30% per diluted share
•Company raises both full-year 2026 net revenues growth outlook to 5.25% - 6.75% and Adjusted EBITDA growth outlook to 5.75% - 7.25%, on a constant currency basis
CLEVELAND, OH, August 6, 2026 – Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and six- months ended June 30, 2026.
“We delivered another strong quarter, with high-single-digit growth, reflecting focused execution across all three of our business units,” said Chief Executive Officer Alton Shader. “These results further underscore the essential nature of Sotera Health’s offerings to healthcare. Since joining the Company, I have been impressed by the dedication of our teams, the trust our customers place in us and the industry-leading expertise that differentiates our business in highly regulated healthcare markets. Together, these strengths position us well to deliver consistent and reliable growth.”
Shader continued, “Based on our strong first-half performance and confidence in the remainder of the year, we are raising our full-year 2026 outlook. I am excited about the numerous opportunities we have for growth as we continue to deepen our customer relationships, invest in our people, facilities and capabilities, and execute on our long-term strategy.”
Second-Quarter 2026 Highlights
(All comparisons are against second quarter of 2025, unless otherwise noted)
•Delivered strong, high-single-digit top- and bottom-line constant currency growth
•Expanded Adjusted EBITDA margin(1) to 51.6%
•Sterigenics: 7.0% constant currency revenue growth; segment income margin improvement of 53 basis points
•Nordion: 16.7% constant currency revenue growth; segment income margin improvement of 160 basis points
•Nelson Labs: 5.4% constant currency revenue growth; sequential segment income margin improvement of 438 basis points
•Net cash provided by operating activities of $88 million
•June 30, 2026, Net Leverage Ratio(1) of 3.0x; achieved long-term target range of 2.0x to 3.0x; available liquidity of approximately $950 million
(1) This is a non-GAAP financial measure used throughout this press release; please refer to the section “Non-GAAP Financial Measures” for explanations of our non-GAAP financial measures and the schedules provided later in this release for reconciliations of reported GAAP to non-GAAP financial measures.
•Repriced term loan, saving approximately $3.5 million of annual interest expense
•Completed final private equity sponsor secondary offering, with no remaining sponsor ownership
Second-Quarter and First-Half 2026 Review by Business Segment
(All comparisons are against second quarter of 2025, unless otherwise noted)
Sterigenics
Sterigenics delivered strong second-quarter 2026 results, with net revenues up 8.6% to $212 million, or 7.0% on a constant currency basis. Segment income improved to $118 million, an increase of 9.6%. For the first six months of 2026, Sterigenics net revenues increased 9.1% to $398 million, or 6.6% on a constant currency basis. Segment income increased 9.6% to $215 million.
Second-quarter net revenues growth was driven by favorable pricing, improved volume/mix and a foreign currency benefit. Segment income and segment income margin also benefited from these factors, partially offset by inflation.
Nordion
Nordion net revenues were up 15.8% to $49 million, or 16.7% on a constant currency basis while segment income increased 19.2% to $28 million. For the first six months of 2026, Nordion net revenues increased 21.6% to $91 million, or 20.8% on a constant currency basis. Segment income increased 26.4% to $52 million.
Second-quarter net revenues growth was driven by improved volume/mix, primarily due to the timing of Cobalt-60 harvests and favorable pricing, partially offset by foreign currency. Segment income and segment income margin also benefited from these factors, partially offset by inflation.
Nelson Labs
Nelson Labs delivered strong second-quarter net revenues growth of 6.3% to $61 million, or 5.4% on a constant currency basis. Segment income improved to $20 million, an increase of 0.6%. For the first six months of 2026, Nelson Labs net revenues improved 2.9% to $113 million, or 0.9% on a constant currency basis, while segment income decreased 4.9% to $34 million.
Second-quarter net revenues and segment income growth were driven by favorable pricing, improved volume/mix and a foreign currency benefit. Segment income margin was impacted by higher costs.
Balance Sheet and Liquidity
As of June 30, 2026, Sotera Health had $2.2 billion of total debt, and $357 million in unrestricted cash and cash equivalents, compared to $2.2 billion in total debt and $345 million in unrestricted cash and cash equivalents as of December 31, 2025. Sotera Health’s Net Leverage Ratio as of June 30, 2026 improved to 3.0x, achieving the Company’s long-term net leverage ratio target range of 2.0x to 3.0x. As of June 30, 2026, available liquidity increased to approximately $950 million, and the Company had no outstanding borrowings under its $600 million revolving credit facility.
2
Full-Year 2026 Outlook
Today, Sotera Health is raising its 2026 outlook:
•Net revenues range raised to $1.236 billion to $1.254 billion, representing constant currency growth of 5.25% to 6.75% and an estimated 100 basis points of foreign currency benefit
•Adjusted EBITDA range raised to $634 million to $643 million, representing constant currency growth of 5.75% to 7.25% and an estimated 100 basis points of foreign currency benefit
•Interest expense improved to a range of $135 million to $142 million
•Tax rate applicable to Adjusted Net Income(1) improved to a range of 27.0% to 28.0%
•Adjusted EPS improved to a range of $0.95 to $1.01
•A weighted-average fully diluted share count in the range of 289 million to 291 million shares
•Capital expenditures in the range of $200 million to $225 million
The Company does not provide a reconciliation for non-GAAP financial measures on a forward-looking basis where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items without unreasonable effort. The Company cannot reconcile its expected Adjusted EBITDA,
Tax Rate Applicable to Adjusted Net Income, Adjusted Net Income and Adjusted EPS without unreasonable effort because certain items that impact net income, earnings per share and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time, including uncertainties caused by changes to the regulatory landscape, restructuring items and certain fair value measurements, all of which are potential adjustments for future earnings.
The outlook provided above contains a number of assumptions, including, among others, the Company’s current expectations regarding supply chain continuity, particularly for the supply of ethylene oxide (“EO”) and Cobalt-60, and the impact of inflationary trends, including their impact on energy prices and the supply of labor. Our outlook is based on current plans and expectations and is subject to several known and unknown risks and uncertainties, including those set forth below under “Cautionary Note Regarding Forward-Looking Statements.”
Earnings Webcast
Sotera Health management will host a conference call and live webcast to discuss the Company’s operating highlights and financial results at 9:00 a.m. Eastern Daylight Time today. A live webcast of the conference call will be accessible at this link or via the Investor Relations section of the Company’s website at Presentation & Events | Sotera Health, along with accompanying materials. A replay of the webcast will be archived on the Company’s website.
Upcoming Investor Events
•Wells Fargo 21st Annual Healthcare Conference at 1:30 p.m. Eastern Daylight Time, September 9, 2026
Cautionary Note Regarding Forward-Looking Statements
Unless expressly indicated or the context requires otherwise, the terms “Sotera Health,” “Company,” “we,” “us,” and “our” in this release refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and reflects management’s expectations about future events and the Company’s operating plans and performance and speak only as of the date hereof. Forward-looking statements present our current forecasts and estimates of future events. These statements do not strictly relate to historical or current results and can be identified by words such as “anticipate,” “appear,” “assume,” “believe,” “estimate,” “expect,”
(1) This is a non-GAAP financial measure used throughout this press release; please refer to the section “Non-GAAP Financial Measures” for explanations of our non-GAAP financial measures.
3
“forecast,” “intend,” “likely,” “may,” “plan,” “project,” “seek,” “should,” “strategy,” “will” and other terms of similar meaning or import in connection with any discussion of future operating, financial or other performance. These forward-looking statements are subject to risks, uncertainties and other factors and actual results may differ materially from those results projected in the statements. These forward-looking statements are subject to various risks, uncertainties and assumptions relating to our operations, financial results, financial condition, business, prospects, growth strategy and liquidity. These risks and uncertainties include, but are not limited to, a disruption in the availability or supply of, or increases in the price of, EO, Co-60 or our other direct materials, services and supplies, including as a result of geopolitical instability and/or sanctions against Russia by the United States, Canada, the United Kingdom and/or the European Union, or sanctions by Russia against those countries; fluctuations in foreign currency exchange rates; evolving changes in environmental, health and safety regulations; health and safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials such as EO and Co-60; the impact and outcome of current and future legal proceedings and liability claims, including litigation related to the use, emissions and releases of EO from our current and former EO sterilization facilities, and the possibility that additional claims will be made in the future; allegations of our failure to properly perform services and potential product liability claims, recalls, penalties and reputational harm; compliance with the extensive regulatory requirements to which we are subject, the related costs, and any failures to receive or maintain, or delays in receiving, required clearances or approvals; adverse changes in industry trends; competition we face; market conditions and changes, including inflationary trends and the impact of tariffs, that impact our long-term supply contracts with variable price clauses and increase our cost of revenues; business continuity hazards, including supply chain disruptions, federal government shutdowns, and other risks associated with our operations; the risks of doing business internationally, including global and regional economic and political instability and compliance with various applicable laws and potentially inconsistent laws and regulations in multiple jurisdictions; our ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner and renew leases for our leased facilities; our ability to attract and retain qualified employees; severe health events or environmental events; cybersecurity incidents, unauthorized data disclosures, and our dependence on information technology systems; the risks associated with the introduction of artificial intelligence technology; an inability to pursue strategic transactions, find suitable acquisition targets, or integrate strategic acquisitions into our business successfully; our ability to maintain effective internal control over financial reporting; our reliance on intellectual property rights to maintain our competitive position and the risk of claims from third parties that we have infringed or misappropriated, or are infringing or misappropriating, their intellectual property rights; our ability to comply with rapidly evolving data privacy and security laws and regulations in various jurisdictions and any ineffective compliance efforts with such laws and regulations; our ability to generate profitability in future periods; impairment charges on our goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives; the effects of unionization efforts and labor regulations in countries in which we operate; adverse changes to our tax positions in U.S. or non-U.S. jurisdictions or the interpretation and application of U.S. tax legislation or other changes in U.S. or non-U.S. taxation of our operations; and our significant degree of leverage and how this leverage could adversely affect our ability to raise additional capital, limit our ability to react to challenges facing our Company or broader changes in our industry or the economy, limit our flexibility in operating our business through restrictions contained in our debt agreements and/or prevent us from meeting our obligations under our existing and future agreements governing our indebtedness. For additional discussion of these risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, such as its Annual Report on Form 10-K and quarterly reports. We do not undertake any obligation to publicly update or revise these forward-looking statements, except as otherwise required by law.
Non-GAAP Financial Measures
To supplement our consolidated financial statements presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), we consider Adjusted EBITDA, Adjusted EBITDA margin, Tax Rate Applicable to Adjusted Net Income, Adjusted Net Income, Adjusted EPS, Net Debt, Net Leverage Ratio and constant currency, each of which is a financial measure not based on any standardized methodology prescribed by GAAP.
4
•We define Adjusted Net Income as net income (loss) before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period.
•We define Adjusted EBITDA as Adjusted Net Income before interest expense, depreciation (including depreciation of Cobalt-60 used in our operations) and income tax provision applicable to Adjusted Net Income.
•Adjusted EBITDA margin is equal to Adjusted EBITDA divided by net revenues.
•We define Adjusted EPS as Adjusted Net Income divided by the weighted average number of diluted shares outstanding.
•Our Net Debt is equal to our total debt, net of unamortized debt issuance costs and debt discounts, less cash and cash equivalents.
•Our Net Leverage Ratio is equal to Net Debt divided by Adjusted EBITDA.
•Tax Rate Applicable to Adjusted Net Income represents the difference between the income tax provision as determined under U.S. GAAP and the income tax benefit/provision associated with pre-tax adjustments used to calculate Adjusted Net Income.
Constant currency is a non-GAAP financial measure we use to assess performance excluding the impact of foreign currency exchange rate changes. We calculate constant currency net revenues by translating prior year net revenues in local currency at the average exchange rates applicable for the current period. The translated results are then used to determine year-over-year percentage increases or decreases. We generally refer to such amounts calculated on a constant currency basis as excluding the impact of foreign currency exchange rates. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.
We use these non-GAAP financial measures as the principal measures of our operating performance. Management believes these measures allow management to more effectively evaluate our operating performance and compare the results of our operations from period to period without the impact of certain non-cash items and non-routine items that we do not expect to continue at the same level in the future and other items that are not core to our operations. We believe that these measures are useful to our investors because they provide a more complete understanding of the factors and trends affecting our business than could be obtained without these measures and their disclosure. In addition, we believe these measures will assist investors in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. Our management also uses these measurements in their financial analysis and operational decision-making and Adjusted EBITDA serves as the key metric for the attainment of our primary annual incentive program. These measures may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.
About Sotera Health
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
Updates on recent developments in matters relevant to investors can be found on the Investor Relations section of the Sotera Health website at Investor Relations | Sotera Health. For developments related to EO, updates can be found at Ethylene Oxide | Sotera Health.
5
INVESTOR RELATIONS
Jason Peterson
Vice President Investor Relations, Sotera Health
IR@soterahealth.com
MEDIA
Kristin Gibbs
Chief Marketing Officer, Sotera Health
kgibbs@soterahealth.com
Source: Sotera Health Company
###
6
Sotera Health Company
Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||
| Service | $ | 278,325 | $ | 257,244 | $ | 519,933 | $ | 481,184 | |||||||||||||||
| Product | 43,050 | 37,097 | 81,487 | 67,680 | |||||||||||||||||||
Total net revenues | 321,375 | 294,341 | 601,420 | 548,864 | |||||||||||||||||||
| Cost of revenues: | |||||||||||||||||||||||
| Service | 126,840 | 113,293 | 245,668 | 220,922 | |||||||||||||||||||
| Product | 16,572 | 14,427 | 30,720 | 25,889 | |||||||||||||||||||
Total cost of revenues | 143,412 | 127,720 | 276,388 | 246,811 | |||||||||||||||||||
Gross profit | 177,963 | 166,621 | 325,032 | 302,053 | |||||||||||||||||||
| Selling, general and administrative expenses | 68,156 | 68,893 | 136,367 | 131,954 | |||||||||||||||||||
| Amortization of intangible assets | 3,015 | 9,298 | 6,046 | 24,625 | |||||||||||||||||||
Illinois EO litigation settlements | — | 34,000 | — | 64,943 | |||||||||||||||||||
| Interest expense, net | 34,405 | 40,651 | 69,150 | 81,527 | |||||||||||||||||||
| Loss on refinancing of debt | 936 | 80 | 936 | 80 | |||||||||||||||||||
| Foreign exchange (gain) loss, net | (3,746) | 627 | (4,317) | 916 | |||||||||||||||||||
| Other income, net | (2,854) | (5,825) | (3,814) | (6,066) | |||||||||||||||||||
Income before income taxes | 78,051 | 18,897 | 120,664 | 4,074 | |||||||||||||||||||
| Provision for income taxes | 24,408 | 10,935 | 40,432 | 9,372 | |||||||||||||||||||
Net income (loss) | $ | 53,643 | $ | 7,962 | $ | 80,232 | $ | (5,298) | |||||||||||||||
| Earnings (Loss) per share: | |||||||||||||||||||||||
| Basic | $ | 0.19 | $ | 0.03 | $ | 0.28 | $ | (0.02) | |||||||||||||||
| Diluted | 0.19 | 0.03 | 0.28 | (0.02) | |||||||||||||||||||
| Weighted average number of common shares outstanding: | |||||||||||||||||||||||
| Basic | 285,773 | 283,933 | 285,333 | 283,747 | |||||||||||||||||||
| Diluted | 288,148 | 285,756 | 287,915 | 283,747 | |||||||||||||||||||
7
Sotera Health Company
Segment Data
(in thousands)
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Segment revenues: | |||||||||||||||||||||||
| Sterigenics | $ | 211,571 | $ | 194,839 | $ | 397,706 | $ | 364,523 | |||||||||||||||
| Nordion | 49,149 | 42,431 | 91,158 | 74,988 | |||||||||||||||||||
| Nelson Labs | 60,655 | 57,071 | 112,556 | 109,353 | |||||||||||||||||||
Total net revenues | $ | 321,375 | $ | 294,341 | $ | 601,420 | $ | 548,864 | |||||||||||||||
| Segment income: | |||||||||||||||||||||||
| Sterigenics | $ | 118,125 | $ | 107,745 | $ | 214,539 | $ | 195,749 | |||||||||||||||
| Nordion | 27,980 | 23,477 | 51,691 | 40,899 | |||||||||||||||||||
| Nelson Labs | 19,634 | 19,513 | 34,162 | 35,926 | |||||||||||||||||||
Total segment income | $ | 165,739 | $ | 150,735 | $ | 300,392 | $ | 272,574 | |||||||||||||||
Less adjustments: | |||||||||||||||||||||||
| Interest expense, net | $ | 34,405 | $ | 40,651 | $ | 69,150 | $ | 81,527 | |||||||||||||||
Depreciation and amortization(a) | 33,328 | 34,948 | 64,072 | 75,682 | |||||||||||||||||||
Share-based compensation(b) | 7,383 | 8,149 | 21,825 | 15,418 | |||||||||||||||||||
Loss on refinancing of debt(c) | 936 | 80 | 936 | 80 | |||||||||||||||||||
Gain on foreign currency and derivatives not designated as hedging instruments, net(d) | (4,270) | (3,018) | (3,646) | (1,127) | |||||||||||||||||||
Business optimization expenses(e) | 1,923 | 2,430 | 2,880 | 4,477 | |||||||||||||||||||
Professional services relating to EO sterilization facilities(f) | 13,349 | 14,035 | 23,204 | 26,363 | |||||||||||||||||||
Illinois EO litigation settlements(g) | — | 34,000 | — | 64,943 | |||||||||||||||||||
Accretion of asset retirement obligation(h) | 634 | 563 | 1,307 | 1,137 | |||||||||||||||||||
| Consolidated income before income taxes | $ | 78,051 | $ | 18,897 | $ | 120,664 | $ | 4,074 | |||||||||||||||
(a) Includes depreciation of Co-60 held at gamma irradiation sites and excludes accelerated depreciation associated with business optimization activities.
(b) Represents share-based compensation expense related to employees and Non-Employee Directors.
(c) Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the Refinancing Term Loans and the Revolving Credit Facility.
(d) Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.
(e) Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with the secondary offerings and shareholder engagement.
(f) Represents litigation and other professional fees associated with our EO sterilization facilities.
(g) Represents (i) the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025 and (ii) the cost to settle 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on July 23, 2025.
(h) Represents non-cash accretion of asset retirement obligations (“ARO”) related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.
8
Sotera Health Company
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
| As of June 30, | As of December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 356,727 | $ | 346,456 | |||||||
| Accounts receivable, net | 150,538 | 139,329 | |||||||||
| Inventories, net | 56,372 | 54,375 | |||||||||
| Other current assets | 82,821 | 73,250 | |||||||||
| Total current assets | 646,458 | 613,410 | |||||||||
| Property, plant, and equipment, net | 1,167,667 | 1,130,564 | |||||||||
| Operating lease assets | 30,919 | 33,393 | |||||||||
| Other intangible assets, net | 270,171 | 288,227 | |||||||||
| Goodwill | 1,091,255 | 1,103,232 | |||||||||
| Other assets | 100,320 | 94,364 | |||||||||
| Total assets | $ | 3,306,790 | $ | 3,263,190 | |||||||
| Liabilities and equity | |||||||||||
| Total current liabilities | $ | 231,238 | $ | 249,584 | |||||||
| Long-term debt, less current portion | 2,125,534 | 2,126,724 | |||||||||
| Other noncurrent liabilities | 202,791 | 209,772 | |||||||||
| Deferred income taxes | 81,579 | 71,075 | |||||||||
| Total liabilities | 2,641,142 | 2,657,155 | |||||||||
| Total equity | 665,648 | 606,035 | |||||||||
| Total liabilities and equity | $ | 3,306,790 | $ | 3,263,190 | |||||||
9
Sotera Health Company
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
| Six Months Ended June 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| Operating activities: | |||||||||||
| Net income (loss) | $ | 80,232 | $ | (5,298) | |||||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||||||||
| Non-cash items | 98,732 | 84,361 | |||||||||
| Changes in operating assets and liabilities | (61,034) | 33,874 | |||||||||
| Net cash provided by operating activities | 117,930 | 112,937 | |||||||||
| Investing activities: | |||||||||||
| Purchases of property, plant and equipment | (92,615) | (51,147) | |||||||||
| Other investing activities | 4,188 | 37 | |||||||||
| Net cash used in investing activities | (88,427) | (51,110) | |||||||||
| Financing activities: | |||||||||||
| Payments on long-term borrowings | (3,558) | (7,547) | |||||||||
| Payments of debt issuance costs | (878) | (2,326) | |||||||||
| Shares withheld for employee taxes on equity awards | (9,074) | (3,654) | |||||||||
| Other financing activities | (1,674) | (1,493) | |||||||||
| Net cash used in financing activities | (15,184) | (15,020) | |||||||||
| Effect of exchange rate changes on cash and cash equivalents | (4,048) | 8,600 | |||||||||
| Net increase in cash and cash equivalents, including restricted cash | 10,271 | 55,407 | |||||||||
| Cash and cash equivalents, including restricted cash, at beginning of period | 346,456 | 278,865 | |||||||||
| Cash and cash equivalents, including restricted cash, at end of period | $ | 356,727 | $ | 334,272 | |||||||
| Supplemental disclosures of cash flow information: | |||||||||||
| Cash paid during the period for interest | $ | 85,088 | $ | 102,716 | |||||||
| Cash paid during the period for income taxes, net of tax refunds received | 24,158 | 32,207 | |||||||||
| Purchases of property, plant and equipment included in accounts payable | 35,397 | 10,307 | |||||||||
10
Sotera Health Company
Non-GAAP Financial Measures
(in thousands, except per share amounts)
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
Net income (loss) | $ | 53,643 | $ | 7,962 | $ | 80,232 | $ | (5,298) | |||||||||||||||
Amortization of intangible assets | 5,563 | 11,924 | 11,165 | 30,598 | |||||||||||||||||||
Share-based compensation(a) | 7,383 | 8,149 | 21,825 | 15,418 | |||||||||||||||||||
Loss on refinancing of debt(b) | 936 | 80 | 936 | 80 | |||||||||||||||||||
Gain on foreign currency and derivatives not designated as hedging instruments, net(c) | (4,270) | (3,018) | (3,646) | (1,127) | |||||||||||||||||||
Business optimization expenses(d) | 1,923 | 2,430 | 2,880 | 4,477 | |||||||||||||||||||
Professional services relating to EO sterilization facilities(e) | 13,349 | 14,035 | 23,204 | 26,363 | |||||||||||||||||||
Illinois EO litigation settlements(f) | — | 34,000 | — | 64,943 | |||||||||||||||||||
Accretion of asset retirement obligation(g) | 634 | 563 | 1,307 | 1,137 | |||||||||||||||||||
Income tax benefit associated with pre-tax adjustments(h) | (5,200) | (20,063) | (11,576) | (41,485) | |||||||||||||||||||
| Adjusted Net Income | 73,961 | 56,062 | 126,327 | 95,106 | |||||||||||||||||||
| Interest expense, net | 34,405 | 40,651 | 69,150 | 81,527 | |||||||||||||||||||
Depreciation(i) | 27,765 | 23,024 | 52,907 | 45,084 | |||||||||||||||||||
Income tax provision applicable to Adjusted Net Income(j) | 29,608 | 30,998 | 52,008 | 50,857 | |||||||||||||||||||
Adjusted EBITDA(k) | $ | 165,739 | $ | 150,735 | $ | 300,392 | $ | 272,574 | |||||||||||||||
| Net Revenues | $ | 321,375 | $ | 294,341 | $ | 601,420 | $ | 548,864 | |||||||||||||||
| Adjusted EBITDA Margin | 51.6 | % | 51.2 | % | 49.9 | % | 49.7 | % | |||||||||||||||
| Weighted average number of shares outstanding | |||||||||||||||||||||||
| Basic | 285,773 | 283,933 | 285,333 | 283,747 | |||||||||||||||||||
Diluted(l) | 288,148 | 285,756 | 287,915 | 285,684 | |||||||||||||||||||
Earnings (Loss) per share | |||||||||||||||||||||||
| Basic | $ | 0.19 | $ | 0.03 | $ | 0.28 | $ | (0.02) | |||||||||||||||
| Diluted | 0.19 | 0.03 | 0.28 | (0.02) | |||||||||||||||||||
| Adjusted earnings per share | |||||||||||||||||||||||
| Basic | $ | 0.26 | $ | 0.20 | $ | 0.44 | $ | 0.34 | |||||||||||||||
| Diluted | 0.26 | 0.20 | 0.44 | 0.33 | |||||||||||||||||||
(a) Represents share-based compensation expense related to employees and Non-Employee Directors.
(b) Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the Refinancing Term Loans and the Revolving Credit Facility.
(c) Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.
(d) Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with the secondary offerings and shareholder engagement.
(e) Represents litigation and other professional fees associated with our EO sterilization facilities.
(f) Represents (i) the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025 and (ii) the cost to settle 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on July 23, 2025.
(g) Represents non-cash accretion of ARO related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.
(h) Represents the income tax impact of adjustments calculated based on the tax rate applicable to each item. We eliminate the effect of tax rate changes as applied to tax assets and liabilities and unusual items from our presentation of adjusted net income.
(i) Includes depreciation of Co-60 held at gamma irradiation sites and excludes accelerated depreciation associated with business optimization activities.
(j) Represents the difference between the income tax provision as determined under GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (h).
(k) $28.9 million and $24.4 million of the adjustments for the three months ended June 30, 2026 and 2025, respectively, and $55.2 million and $48.6 million of the adjustments for the six months ended June 30, 2026 and 2025, respectively, are included in cost of revenues, primarily consisting of amortization of intangible assets, depreciation, and accretion of asset retirement obligations.
(l) For the six months ended June 30, 2025, the diluted weighted average shares outstanding presented in this table reflects the amount that would be reported under U.S. GAAP if the Company were to have net income in the six months ended June 30, 2025.
11
Sotera Health Company
Non-GAAP Financial Measures
($’s in thousands except Net Leverage)
(unaudited)
| As of June 30, | As of December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| Current portion of long-term debt | $ | 13,923 | $ | 13,973 | |||||||
| Long-term debt | 2,125,534 | 2,126,724 | |||||||||
| Current portion of finance leases | 3,732 | 3,465 | |||||||||
| Finance leases less current portion | 91,575 | 93,835 | |||||||||
| Total Debt | 2,234,764 | 2,237,997 | |||||||||
| Less: cash and cash equivalents | (356,716) | (344,621) | |||||||||
| Net Debt | $ | 1,878,048 | $ | 1,893,376 | |||||||
Adjusted EBITDA(a) | $ | 621,619 | $ | 593,801 | |||||||
| Net Leverage | 3.0x | 3.2x | |||||||||
(a)Represents Adjusted EBITDA for the twelve months ended June 30, 2026 and December 31, 2025, respectively. Refer to the reconciliation of net income (the most comparable GAAP measure) to Adjusted EBITDA on the following page.
12
Sotera Health Company
Non-GAAP Financial Measures
(in thousands)
(unaudited)
| Twelve Months Ended June 30, | Twelve Months Ended December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| Net income | $ | 163,479 | $ | 77,949 | |||||||
Amortization of intangible assets | 22,365 | 41,798 | |||||||||
Share-based compensation(a) | 37,475 | 31,068 | |||||||||
Loss on refinancing of debt(b) | 2,318 | 1,462 | |||||||||
(Gain) Loss on foreign currency and derivatives not designated as hedging instruments, net(c) | (2,461) | 58 | |||||||||
Business optimization expenses(d) | 6,471 | 8,068 | |||||||||
Professional services relating to EO sterilization facilities(e) | 43,066 | 46,225 | |||||||||
Illinois EO litigation settlement(f) | — | 64,943 | |||||||||
Accretion of asset retirement obligation(g) | 2,491 | 2,321 | |||||||||
Income tax provision (benefit) associated with pre-tax adjustments(h) | 1,431 | (28,478) | |||||||||
| Adjusted Net Income | 276,635 | 245,414 | |||||||||
| Interest expense, net | 143,345 | 155,722 | |||||||||
Depreciation(i) | 102,453 | 94,630 | |||||||||
Income tax provision applicable to Adjusted Net Income(j) | 99,186 | 98,035 | |||||||||
Adjusted EBITDA(k) | $ | 621,619 | $ | 593,801 | |||||||
| Net Revenues | $ | 1,216,173 | $ | 1,163,617 | |||||||
| Adjusted EBITDA Margin | 51.1% | 51.0% | |||||||||
(a)Represents share-based compensation expense related to employees and Non-Employee Directors.
(b)Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the Refinancing Term Loans and the Revolving Credit Facility.
(c)Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.
(d)Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting and other fees associated with the secondary offerings and shareholder engagement.
(e)Represents litigation and other professional fees associated with our EO sterilization facilities.
(f)Represents (i) the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025 and (ii) the cost to settle 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on July 23, 2025.
(g)Represents non-cash accretion of ARO related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.
(h)Represents the income tax impact of adjustments calculated based on the tax rate applicable to each item. We eliminate the effect of tax rate changes as applied to tax assets and liabilities and unusual items from our presentation of adjusted net income.
(i)Includes depreciation of Co-60 held at gamma irradiation sites and excludes accelerated depreciation associated with business optimization activities.
(j)Represents the difference between the income tax provision as determined under GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (h).
(k)$106.5 million and $99.9 million of the adjustments for the twelve months ended June 30, 2026 and December 31, 2025, respectively, are included in cost of revenues, primarily consisting of amortization of intangible assets, depreciation, and accretion of asset retirement obligations.
13